3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
23
Not yet recruiting
5
Completed
5
Active not recruiting
3
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Gallbladder Neoplasms
1
Disease Progression
1
Cholangiocarcinoma
1
Bile Duct Neoplasms
1
Interventions
pembrolizumab
28
Carboplatin
18
Cisplatin
15
Nivolumab
13
Pemetrexed
12
Paclitaxel
11
Specimen Handling
10
Ipilimumab
10
Gemcitabine
10
venetoclax
8
durvalumab
8
atezolizumab
8
Radiotherapy
8
Radiosurgery
8
Magnetic Resonance Spectroscopy
8
Docetaxel
7
Cyclophosphamide
7
Biopsy
7
fludarabine
6
enzalutamide
6
Bevacizumab
6
tislelizumab
5
tazemetostat
5
X-Rays
5
Trastuzumab
5
Surveys and Questionnaires
5
Practice Guidelines as Topic
5
Interviews as Topic
5
Injections
5
Dexamethasone
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Folfox protocol
×
90 days
×
Clear all
NCT05712356
2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2
Terminated
66 enrolled
12 charts